3647 results for «686»

Filter By

3647 results

AI adoption in the cathlab of tomorrow - Risk prediction applications

20 May 2026 – From EuroPCR 2026

This session delves into the adoption of artificial intelligence in the cath lab, focusing on clinically useful risk prediction models for coronary and structural interventions. It covers advanced AI-guided intravascular imaging, machine learning applications for adverse event prediction, and critical evaluation of model validation and clinical...

Complex endovascular and pulmonary interventions

20 May 2026 – From EuroPCR 2026

Explore advances in complex endovascular and pulmonary interventions, including the transformation of interventional labs into intelligent learning ecosystems, innovative approaches to peripheral and coronary CTOs, and novel therapies such as extravascular renal denervation and fixation catheters for acute pulmonary embolism.

Mitral paravalvular leak closure: case-bases strategies

20 May 2026 – From EuroPCR 2026

This session presents case-based strategies for mitral paravalvular leak closure, highlighting complex percutaneous approaches including multivalvular failure management, apical access techniques, and transatrial direct surgical valve-in-MAC procedures. It features challenging clinical scenarios demonstrating innovative solutions for hemolytic leaks and complex paravalvular defects.

Management of rare clinical scenarios in the cathlab

20 May 2026 – From EuroPCR 2026

This session addresses the management of rare and complex clinical scenarios encountered in the catheterization laboratory. Cases include dyspnea in coronary artery bypass graft patients, aortocoronary dissection management, complications during coronary sinus reducer implantation, coronary artery aneurysms related to IgG4 vasculitis, ibuprofen-induced Kounis syndrome, and challenging...

A randomised trial comparing imaging-guided PCI with Orsiro vs Xience

18 May 2021

Previous clinical trials suggested that ultra-thin strut biodegradable polymer sirolimus-eluting stent (BP-SES) may be associated with lower target lesion failure (TLF) when compared to durable polymer everolimus-eluting stents (DP-EES). However, the possible underlying mechanisms remain unclear. Therefore, the all-comers CASTLE study was designed to assess the...

Authors :

A randomised trial comparing imaging-guided PCI with Orsiro vs Xience

RIVER: Rivaroxaban for valvular heart disease and atrial fibrillation

05 Sep 2023

Alex Sticchi provides his take on the results of the RIVER trial, which were presented by Pedro Gabriel Barros E Silva during the ESC 2023 congress in Amsterdam.

Rivaroxaban versus Warfarin in Patients with Bioprosthetic Valves According to Valvular Heart Disease Etiology, and Thrombotic and Bleeding Risks: Insights from...

Alessandro Sticchi

Author

Alessandro Sticchi
RIVER: Rivaroxaban for valvular heart disease and atrial fibrillation

BIOFLOW DAPT - Biodegradable-polymer or durable-polymer stents in patients at high bleeding risk: A randomized, open-label clinical trial

26 Aug 2023

Nicola Ryan reports on the BIOFLOW DAPT trial results presented during the ESC 2023 Congress in Amsterdam by Marco Valgimigli and published in Circulation.

BIOFLOW-DAPT is an open-label randomised trial comparing the safety and efficacy of a biodegradable-polymer sirolimus-eluting stent with a durable-polymer zotarolimus-eluting stent in high-bleeding risk patients...

Nicola Ryan

Author

Nicola Ryan
BIOFLOW DAPT - Biodegradable polymer SES vs durable polymer ZES in HBR subjects with 1-month DAPT
Didn’t find what you were looking for?